T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H
Adoptive cell therapy (ACT) with TCR-engineered T-cells represents a promising alternative to TIL- or CAR-T therapies for patients with advanced solid cancers. Currently, selection of therapeutic TCRs critically depends on knowing the target antigens, a condition excluding most patients from treatme...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1509855/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850040570220642304 |
|---|---|
| author | Volker Lennerz Volker Lennerz Volker Lennerz Christoph Doppler Martina Fatho Anja Dröge Sigrid Schaper Kristin Gennermann Nadine Genzel Stephanie Plassmann David Weismann Samuel W. Lukowski Dominik Bents Christina Beushausen Karen Kriese Hermann Herbst Volkhard Seitz Rudolf Hammer Rudolf Hammer Paul J. Adam Stephan Eggeling Catherine Wölfel Thomas Wölfel Steffen Hennig Steffen Hennig |
| author_facet | Volker Lennerz Volker Lennerz Volker Lennerz Christoph Doppler Martina Fatho Anja Dröge Sigrid Schaper Kristin Gennermann Nadine Genzel Stephanie Plassmann David Weismann Samuel W. Lukowski Dominik Bents Christina Beushausen Karen Kriese Hermann Herbst Volkhard Seitz Rudolf Hammer Rudolf Hammer Paul J. Adam Stephan Eggeling Catherine Wölfel Thomas Wölfel Steffen Hennig Steffen Hennig |
| author_sort | Volker Lennerz |
| collection | DOAJ |
| description | Adoptive cell therapy (ACT) with TCR-engineered T-cells represents a promising alternative to TIL- or CAR-T therapies for patients with advanced solid cancers. Currently, selection of therapeutic TCRs critically depends on knowing the target antigens, a condition excluding most patients from treatment. Direct antigen-agnostic identification of tumor-specific T-cell clonotypes and TCR-T manufacturing using their TCRs can advance ACT for patients with aggressive solid cancers. We present a method to identify tumor-specific clonotypes from surgical specimens by comparing TCRβ-chain repertoires of TILs and adjacent tissue-resident lymphocytes. In six out of seven NSCLC-patients analyzed, our selection of tumor-specific clonotypes based on TIL-abundance and high tumor-to-nontumor frequency ratios was confirmed by gene expression signatures determined by scRNA-Seq. In three patients, we demonstrated that predicted tumor-specific clonotypes reacted against autologous tumors. For one of these patients, we engineered TCR-T cells with four candidate tumor-specific TCRs that showed reactivity against the patient’s tumor and HLA-matched NSCLC cell lines. The TCR-T cells were then used to screen for candidate neoantigens and aberrantly expressed antigens. Three TCRs recognized recurrent driver-mutation KRAS Q61H-peptide ILDTAGHEEY presented by HLA-A*01:01. The TCRs were also dominant in a tumor relapse, one was found in cell free DNA. The finding of homologous TCRs in independent KRAS Q61H-positive cancers suggests a therapeutic opportunity for HLA-matched patients with KRAS Q61H-expressing tumors. |
| format | Article |
| id | doaj-art-8b93b9403ffa44d5ac3fee587f923cec |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-8b93b9403ffa44d5ac3fee587f923cec2025-08-20T02:56:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-03-011610.3389/fimmu.2025.15098551509855T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61HVolker Lennerz0Volker Lennerz1Volker Lennerz2Christoph Doppler3Martina Fatho4Anja Dröge5Sigrid Schaper6Kristin Gennermann7Nadine Genzel8Stephanie Plassmann9David Weismann10Samuel W. Lukowski11Dominik Bents12Christina Beushausen13Karen Kriese14Hermann Herbst15Volkhard Seitz16Rudolf Hammer17Rudolf Hammer18Paul J. Adam19Stephan Eggeling20Catherine Wölfel21Thomas Wölfel22Steffen Hennig23Steffen Hennig24Internal Medicine III, University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, GermanyHSDiagnomics GmbH, Berlin, GermanyTheryCell GmbH, Berlin, GermanyInternal Medicine III, University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, GermanyInternal Medicine III, University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, GermanyHSDiagnomics GmbH, Berlin, GermanyHSDiagnomics GmbH, Berlin, GermanyHSDiagnomics GmbH, Berlin, GermanyTheryCell GmbH, Berlin, GermanyTheryCell GmbH, Berlin, GermanyBoehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, AustriaBoehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, AustriaTheryCell GmbH, Berlin, GermanyVivantes Clinic Neukölln, Vivantes Thoracic Surgery, Berlin, GermanyVivantes Pathology, Vivantes Clinic Neukölln, Berlin, GermanyVivantes Pathology, Vivantes Clinic Neukölln, Berlin, GermanyHSDiagnomics GmbH, Berlin, GermanyHSDiagnomics GmbH, Berlin, GermanyTheryCell GmbH, Berlin, GermanyBoehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, AustriaVivantes Clinic Neukölln, Vivantes Thoracic Surgery, Berlin, GermanyInternal Medicine III, University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, GermanyInternal Medicine III, University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, GermanyHSDiagnomics GmbH, Berlin, GermanyTheryCell GmbH, Berlin, GermanyAdoptive cell therapy (ACT) with TCR-engineered T-cells represents a promising alternative to TIL- or CAR-T therapies for patients with advanced solid cancers. Currently, selection of therapeutic TCRs critically depends on knowing the target antigens, a condition excluding most patients from treatment. Direct antigen-agnostic identification of tumor-specific T-cell clonotypes and TCR-T manufacturing using their TCRs can advance ACT for patients with aggressive solid cancers. We present a method to identify tumor-specific clonotypes from surgical specimens by comparing TCRβ-chain repertoires of TILs and adjacent tissue-resident lymphocytes. In six out of seven NSCLC-patients analyzed, our selection of tumor-specific clonotypes based on TIL-abundance and high tumor-to-nontumor frequency ratios was confirmed by gene expression signatures determined by scRNA-Seq. In three patients, we demonstrated that predicted tumor-specific clonotypes reacted against autologous tumors. For one of these patients, we engineered TCR-T cells with four candidate tumor-specific TCRs that showed reactivity against the patient’s tumor and HLA-matched NSCLC cell lines. The TCR-T cells were then used to screen for candidate neoantigens and aberrantly expressed antigens. Three TCRs recognized recurrent driver-mutation KRAS Q61H-peptide ILDTAGHEEY presented by HLA-A*01:01. The TCRs were also dominant in a tumor relapse, one was found in cell free DNA. The finding of homologous TCRs in independent KRAS Q61H-positive cancers suggests a therapeutic opportunity for HLA-matched patients with KRAS Q61H-expressing tumors.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1509855/fullT-cell receptor (TCR)TCR-T celltumor-specific antigenneoantigenKRAS Q61Honcogenic driver gene |
| spellingShingle | Volker Lennerz Volker Lennerz Volker Lennerz Christoph Doppler Martina Fatho Anja Dröge Sigrid Schaper Kristin Gennermann Nadine Genzel Stephanie Plassmann David Weismann Samuel W. Lukowski Dominik Bents Christina Beushausen Karen Kriese Hermann Herbst Volkhard Seitz Rudolf Hammer Rudolf Hammer Paul J. Adam Stephan Eggeling Catherine Wölfel Thomas Wölfel Steffen Hennig Steffen Hennig T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H Frontiers in Immunology T-cell receptor (TCR) TCR-T cell tumor-specific antigen neoantigen KRAS Q61H oncogenic driver gene |
| title | T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H |
| title_full | T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H |
| title_fullStr | T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H |
| title_full_unstemmed | T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H |
| title_short | T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H |
| title_sort | t cell receptors identified by a personalized antigen agnostic screening approach target shared neoantigen kras q61h |
| topic | T-cell receptor (TCR) TCR-T cell tumor-specific antigen neoantigen KRAS Q61H oncogenic driver gene |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1509855/full |
| work_keys_str_mv | AT volkerlennerz tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT volkerlennerz tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT volkerlennerz tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT christophdoppler tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT martinafatho tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT anjadroge tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT sigridschaper tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT kristingennermann tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT nadinegenzel tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT stephanieplassmann tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT davidweismann tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT samuelwlukowski tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT dominikbents tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT christinabeushausen tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT karenkriese tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT hermannherbst tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT volkhardseitz tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT rudolfhammer tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT rudolfhammer tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT pauljadam tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT stephaneggeling tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT catherinewolfel tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT thomaswolfel tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT steffenhennig tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h AT steffenhennig tcellreceptorsidentifiedbyapersonalizedantigenagnosticscreeningapproachtargetsharedneoantigenkrasq61h |